Isha Tanaka 5/2/23 Isha Tanaka 5/2/23

Trojan Horse Drug Delivery: The Future of Medicine and Matinas BioPharma's LNC Technology

David Stone 4/24/23 David Stone 4/24/23

Is BioNTech About to Take a Major Stake in Matinas BioPharma?

John Wilson 4/21/23 John Wilson 4/21/23

Amphotericin B Explained: How It Works, Who Needs It, and What's on the Horizon

Sarah Martinez 4/21/23 Sarah Martinez 4/21/23

The Growing Need for Novel Antifungals

Mark Armstrong 4/20/23 Mark Armstrong 4/20/23

Could the Next Pandemic Be Fungal-Based?

Jim Rogan 4/13/23 Jim Rogan 4/13/23

When should you file an SEC complaint against a company?

Jim Rogan 4/11/23 Jim Rogan 4/11/23

Is Your CEO a Visionary or a Scam Artist? 10 Traits to Help You Decide

John Wilson 4/11/23 John Wilson 4/11/23

10 Red Flags That Indicate Your Company Could Be a Scam

Mark Armstrong 4/11/23 Mark Armstrong 4/11/23

From Vision to Reality: 10 Signs Your CEO Can't Execute Their Strategy

Mark Armstrong 4/8/23 Mark Armstrong 4/8/23

Candida auris: A Growing Health Threat to Hospitalized Patients

Jim Greenlight 4/7/23 Jim Greenlight 4/7/23

12 Signs Your CEO Lacks the Communication Skills to Inspire and Motivate

Jim Rogan 4/7/23 Jim Rogan 4/7/23

Leadership Meltdown: 8 Alarming Signs It's Time to Dump Your Investment

Jim Rogan 4/6/23 Jim Rogan 4/6/23

12 Signs a CEO is Bad and Should Be Fired

Mark Armstrong 3/25/23 Mark Armstrong 3/25/23

Matinas BioPharma Website Goes Offline, Fueling M&A Speculation

David Stone 3/19/23 David Stone 3/19/23

Revolutionizing mRNA Therapeutics: The Promise of a Novel Oral Drug Delivery System

Johnny Satireo 1/10/23 Johnny Satireo 1/10/23

Russia Appoints Jerome Jabbourk as Head of mRNA Research

Johnny Satireo 12/20/22 Johnny Satireo 12/20/22

Biotech CEO Spotted at Airport Trying to Flee the Country

David Stone 6/12/22 David Stone 6/12/22

Matinas appears to be on the verge of signing a deal with BioNTech

GripRoom Research 4/23/22 GripRoom Research 4/23/22

Matinas BioPharma - Insightful social media posts and due diligence

David Stone 4/21/22 David Stone 4/21/22

BioNTech’s Deal with Matinas Could Put Moderna Out of Business